BRIEF-Longeveron announces constructive Type C meeting with U.S. FDA ahead of data readout for ELPIS II Phase 2b clinical trial evaluating treatment for Hypoplastic Left Heart Syndrome

Longeveron

Longeveron

LGVN

0.00

May 8 (Reuters) - Longeveron Inc LGVN.O:

  • LONGEVERON ANNOUNCES CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA AHEAD OF DATA READOUT FOR ELPIS II PHASE 2B CLINICAL TRIAL EVALUATING TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

  • LONGEVERON INC - FDA NO LONGER REFERS TO ELPIS II TRIAL AS PIVOTAL

  • LONGEVERON INC - FDA SAYS NEW PRIMARY ENDPOINT FOR ELPIS II CANNOT BE AGREED WHILE TRIAL ONGOING

Source text: ID:nGNX9kkQlK

Further company coverage: LGVN.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.